Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$103.6b

Regeneron Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Regeneron Pharmaceuticals has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 18.1% per year. Regeneron Pharmaceuticals's return on equity is 15.2%, and it has net margins of 30.1%.

Key information

15.8%

Earnings growth rate

16.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate18.1%
Return on equity15.2%
Net Margin30.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Recent updates

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Aug 07
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Jul 17
Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Apr 17
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Revenue & Expenses Breakdown
Beta

How Regeneron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:REGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2313,1173,9542,6310
30 Sep 2313,0973,9912,5540
30 Jun 2312,6714,2992,4430
31 Mar 2312,3704,1832,2670
31 Dec 2212,1734,3382,1160
30 Sep 2213,7105,3702,0150
30 Jun 2214,2275,6871,9310
31 Mar 2216,5087,9341,8690
31 Dec 2116,0728,0751,8250
30 Sep 2113,5436,9961,5690
30 Jun 2112,3846,2051,4510
31 Mar 219,1984,0041,3840
31 Dec 208,4973,5131,3460
30 Sep 207,9383,1561,4590
30 Jun 207,3872,9841,4370
31 Mar 207,0132,2791,3830
31 Dec 196,5582,1161,3420
30 Sep 196,6222,1441,3810
30 Jun 196,5422,0691,4460
31 Mar 196,5722,4281,5170
31 Dec 185,1462,4441,1270
30 Sep 186,3651,7981,4750
30 Jun 186,2031,5911,4120
31 Mar 186,0651,4281,3540
31 Dec 175,8721,1991,3200
30 Sep 175,5171,2781,2360
30 Jun 175,2361,1551,2000
31 Mar 174,9799631,1850
31 Dec 164,8608961,1780
30 Sep 164,7327971,1470
30 Jun 164,6497431,0870
31 Mar 164,4357419690
31 Dec 154,1046368390
30 Sep 153,8085717190
30 Jun 153,3964446530
31 Mar 153,0633465750
31 Dec 142,8203385190
30 Sep 142,6283454260
30 Jun 142,4994033800
31 Mar 142,2913943550
31 Dec 132,1054143460
30 Sep 131,9097983050
30 Jun 131,7408482540
31 Mar 131,5868372300

Quality Earnings: REGN has high quality earnings.

Growing Profit Margin: REGN's current net profit margins (30.1%) are lower than last year (35.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown by 15.8% per year over the past 5 years.

Accelerating Growth: REGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: REGN had negative earnings growth (-8.9%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).


Return on Equity

High ROE: REGN's Return on Equity (15.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.